HBsAg seroclearance further reduces hepatocellular carcinoma but not hepatic decompensation in patients with cirrhosis and complete viral suppression
Listen to this summary
The authors aimed to determine whether HBsAg seroclearance offers additional clinical benefits over complete viral suppression in patients with chronic hepatitis B and cirrhosis. Their findings indicate that while HBsAg seroclearance significantly reduces the risk of hepatocellular carcinoma (HCC), it does not affect the risk of hepatic decompensation compared to patients with only complete viral suppression.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Hepatology (Baltimore, Md.)
View all →Jun 11, 2026 · Hepatology (Baltimore, Md.)
Macrophage-neutrophil crosstalk via the Selplg-Sell-YAP axis drives NETosis and MASH-associated liver fibrosis
Jun 10, 2026 · Hepatology (Baltimore, Md.)
Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
